Ektachem bilirubin fraction Bc as a predictor of liver transplant rejection

Catherine J. Cox, Ronald Valdiserri, Tony R. Zerbe, Janet L. Genter

Research output: Contribution to journalArticle

Abstract

Bilirubin fractions Be and DELTA, not routinely available prior to the EKTACHEM Chemistry Analyzer and its slide methodology, were studied in an outpatient population of liver transplant recipients. A preliminary evaluation by the authors has shown that direct bilirubin (DBILI) levels in the normal range consist almost exclusively of DELTA (protein-bound conjugated bilirubin), while at elevated DBILI levels, an increasing amount of Be (non-protein-bound conjugated bilirubin) is measured as well. The present study evaluated the clinical significance of Be in the serum of 80 liver transplant recipients as a means of identifying episodes of rejection. Each patient was classified into rejection or nonrejection categories based on clinical status, liver biopsy results, and/or response to therapy. Eighteen patients were classified as experiencing an episode of rejection during the period of this study. Fourteen of these (77.8%) had Be levels that ranged from 0.1 to 6.8 mg/ dl. Sixty two patients were classified in the nonrejection category. Fourteen (22.6%) of these patients had Be levels that ranged from 0.1 to 0.6 mg/dl. In our outpatient liver transplant recipients with Be ≥0.1 mg/dl, the relative risk of rejection (% of rejection patients with Bc/% of nonrejection patients with Be) was 3.44. This value indicates that Be determination may be a helpful adjunct in the assessment of rejection.

Original languageEnglish (US)
Pages (from-to)536-539
Number of pages4
JournalTransplantation
Volume44
Issue number4
StatePublished - 1987
Externally publishedYes

Fingerprint

Graft Rejection
Bilirubin
Liver
Outpatients
Reference Values
Biopsy
Serum
Population
Transplant Recipients
Proteins

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Ektachem bilirubin fraction Bc as a predictor of liver transplant rejection. / Cox, Catherine J.; Valdiserri, Ronald; Zerbe, Tony R.; Genter, Janet L.

In: Transplantation, Vol. 44, No. 4, 1987, p. 536-539.

Research output: Contribution to journalArticle

Cox, CJ, Valdiserri, R, Zerbe, TR & Genter, JL 1987, 'Ektachem bilirubin fraction Bc as a predictor of liver transplant rejection', Transplantation, vol. 44, no. 4, pp. 536-539.
Cox, Catherine J. ; Valdiserri, Ronald ; Zerbe, Tony R. ; Genter, Janet L. / Ektachem bilirubin fraction Bc as a predictor of liver transplant rejection. In: Transplantation. 1987 ; Vol. 44, No. 4. pp. 536-539.
@article{3deb4ea477a745bea304b4ab75b24416,
title = "Ektachem bilirubin fraction Bc as a predictor of liver transplant rejection",
abstract = "Bilirubin fractions Be and DELTA, not routinely available prior to the EKTACHEM Chemistry Analyzer and its slide methodology, were studied in an outpatient population of liver transplant recipients. A preliminary evaluation by the authors has shown that direct bilirubin (DBILI) levels in the normal range consist almost exclusively of DELTA (protein-bound conjugated bilirubin), while at elevated DBILI levels, an increasing amount of Be (non-protein-bound conjugated bilirubin) is measured as well. The present study evaluated the clinical significance of Be in the serum of 80 liver transplant recipients as a means of identifying episodes of rejection. Each patient was classified into rejection or nonrejection categories based on clinical status, liver biopsy results, and/or response to therapy. Eighteen patients were classified as experiencing an episode of rejection during the period of this study. Fourteen of these (77.8{\%}) had Be levels that ranged from 0.1 to 6.8 mg/ dl. Sixty two patients were classified in the nonrejection category. Fourteen (22.6{\%}) of these patients had Be levels that ranged from 0.1 to 0.6 mg/dl. In our outpatient liver transplant recipients with Be ≥0.1 mg/dl, the relative risk of rejection ({\%} of rejection patients with Bc/{\%} of nonrejection patients with Be) was 3.44. This value indicates that Be determination may be a helpful adjunct in the assessment of rejection.",
author = "Cox, {Catherine J.} and Ronald Valdiserri and Zerbe, {Tony R.} and Genter, {Janet L.}",
year = "1987",
language = "English (US)",
volume = "44",
pages = "536--539",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Ektachem bilirubin fraction Bc as a predictor of liver transplant rejection

AU - Cox, Catherine J.

AU - Valdiserri, Ronald

AU - Zerbe, Tony R.

AU - Genter, Janet L.

PY - 1987

Y1 - 1987

N2 - Bilirubin fractions Be and DELTA, not routinely available prior to the EKTACHEM Chemistry Analyzer and its slide methodology, were studied in an outpatient population of liver transplant recipients. A preliminary evaluation by the authors has shown that direct bilirubin (DBILI) levels in the normal range consist almost exclusively of DELTA (protein-bound conjugated bilirubin), while at elevated DBILI levels, an increasing amount of Be (non-protein-bound conjugated bilirubin) is measured as well. The present study evaluated the clinical significance of Be in the serum of 80 liver transplant recipients as a means of identifying episodes of rejection. Each patient was classified into rejection or nonrejection categories based on clinical status, liver biopsy results, and/or response to therapy. Eighteen patients were classified as experiencing an episode of rejection during the period of this study. Fourteen of these (77.8%) had Be levels that ranged from 0.1 to 6.8 mg/ dl. Sixty two patients were classified in the nonrejection category. Fourteen (22.6%) of these patients had Be levels that ranged from 0.1 to 0.6 mg/dl. In our outpatient liver transplant recipients with Be ≥0.1 mg/dl, the relative risk of rejection (% of rejection patients with Bc/% of nonrejection patients with Be) was 3.44. This value indicates that Be determination may be a helpful adjunct in the assessment of rejection.

AB - Bilirubin fractions Be and DELTA, not routinely available prior to the EKTACHEM Chemistry Analyzer and its slide methodology, were studied in an outpatient population of liver transplant recipients. A preliminary evaluation by the authors has shown that direct bilirubin (DBILI) levels in the normal range consist almost exclusively of DELTA (protein-bound conjugated bilirubin), while at elevated DBILI levels, an increasing amount of Be (non-protein-bound conjugated bilirubin) is measured as well. The present study evaluated the clinical significance of Be in the serum of 80 liver transplant recipients as a means of identifying episodes of rejection. Each patient was classified into rejection or nonrejection categories based on clinical status, liver biopsy results, and/or response to therapy. Eighteen patients were classified as experiencing an episode of rejection during the period of this study. Fourteen of these (77.8%) had Be levels that ranged from 0.1 to 6.8 mg/ dl. Sixty two patients were classified in the nonrejection category. Fourteen (22.6%) of these patients had Be levels that ranged from 0.1 to 0.6 mg/dl. In our outpatient liver transplant recipients with Be ≥0.1 mg/dl, the relative risk of rejection (% of rejection patients with Bc/% of nonrejection patients with Be) was 3.44. This value indicates that Be determination may be a helpful adjunct in the assessment of rejection.

UR - http://www.scopus.com/inward/record.url?scp=0023640109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023640109&partnerID=8YFLogxK

M3 - Article

C2 - 3313842

AN - SCOPUS:0023640109

VL - 44

SP - 536

EP - 539

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 4

ER -